U.S. researchers have uncovered a plethora of mechanisms in ALK-rearranged lung cancers that could drive resistance to Pfizer's Xalkori crizotinib. The findings suggest that Xalkori, and possibly other ALK inhibitors, should be combined with drugs that target the EGFR and KIT pathways.